Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes

Inclusion Criteria: * Diagnosis of Type 1 Diabetes mellitus (T1DM) * Central laboratory C-peptide \< 0.7 ng/ml (0.23 nmol/L) * Insulin use for at least 12 months per patient reported or medical records * Method of insulin administration (MDI or CSII) must have been unchanged for at least 3 months prior to screening * Subjects must be on a total insulin dose of ≥ 0.3 U/kg/day for at least 3 months prior to screening * If on MDI insulin administration, subject must be on ≥ 3x injections per day * Screening Visit: Central laboratory HbA1c ≥ 7.7% and ≤ 11.0% * Body mass index (BMI) ≥ 18.5 kg/m2 Exclusion Criteria: * History of Type 2 Diabetes mellitus (T2DM) or maturity onset diabetes of the young (MODY), pancreatic surgery, or chronic pancreatitis that could result in decreased beta cell capacity * Taking any non-insulin antihyperglicemic agent within 1 month prior to screening * Taking GLP-1 receptor agonist within 2 months prior to screening for once weekly administration and within 1 month prior to screening for once or twice daily administration * Taking metformin and/or thiazolidinediones within 2 months prior to screening * History of diabetes ketoacidosis requiring medical intervention within 1 month prior to screening * History of hospital admission for glycemic control (either hyperglycemia or hypoglycemia) within 1 month prior to screening * Frequent episodes of severe hypoglycemia (more than one episode requiring medical assistance, emergency care), and/or glucagon therapy administered by a third-party individual within 1 month prior to screening * History of Addison's disease